MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'inhaled insulin'. Sat, 03 Sep 2011 02:20:30 +0100 http://www.medworm.com/index.php?rid=5125969&cid=t_118065_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FP452Yvu9Hlk%2F And so yet another working week will soon draw to a close. Not a moment to soon, yes? This is, of course, our treasured signal to daydream about weekend plans. Our own agenda includes taking one of the short people to a soccer match, catching up on some reading and tidying up around the Pharmalot corporate campus. In other words, a few small pleasures. And what about you? How about a day at the beach or a ride in the country? Maybe curl up with an e-book? Or a shopping trip to stimulate what is left of the economy? Whatever you do, have a grand time, and be safe. See you soon… US Ambassador Tells Czechs Not To Auction Meds Online (Prague Daily Monitor) Icahn Wants To Narrow Forest’s Research Focus (Bloomberg News) MannKind Claims To Have Clear Path Forward On Afrezza (Pharma Ti... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=5125969 Fri, 12 Aug 2011 12:09:49 +0100 5125969 http://www.medworm.com/index.php?rid=5107899&cid=t_118065_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FRkVSK5_Bu9Y%2F Good morning, everyone, and nice to see you again. We hope the weekend was invigorating. Now, of course, the time has come to resume the routine of meetings and deadlines, even if it is a slow time of year. To get started, yes, we are brewing that mandatory cup of stimulation, so feel free to join us. Meanwhile, here are some tidibts from around the world. Hope your day goes well and stay in touch… Pfizer And UCSD Collaborate On Early Drug Discovery (San Diego Union Tribune) China’s Healthcare Push May Curb Sales For Brand-Name Pharma (Bloomberg News) Nestle Eyes Pfizer Formula Milk Powder Business (Business China) EU Approves Botox For Treating Urinary Incontinence (Reuters) Takeda Pharmaceuticals Faces Rising Number Of Actos Lawsuits (Associated Press) Bayer Is Eyeing Pfizer ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=5107899 Mon, 08 Aug 2011 11:50:32 +0100 5107899 http://www.medworm.com/index.php?rid=4696953&cid=t_118065_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F3rag4hFYoo8%2F Might the FDA be giving MannKind the bum’s rush? Late Friday, the agency cancelled an end-of-review meeting designed to discuss the Afrezza inhaled insulin device that earlier this year was the subject of a second complete response letter. The reason for the cancellation? The potential for a government shutdown. The FDA, meanwhile, did not reschedule the meeting (see the statement). The move is the latest incident in which at least one Wall Street analyst believes the agency appears to be sending a decidedly chilly message to the MannKind team, which was asked in January to provide more safety data about Alfrezza and run two new trials - one with Type 1 diabetes patients and another with Type 2 diabetes patients (back story). “While the FDA cancelled the meeting with MannKind, ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4696953 Mon, 11 Apr 2011 12:15:15 +0100 4696953 http://www.medworm.com/index.php?rid=4464704&cid=t_118065_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FZKhyl5OMgyc%2F For the past few years, Al Mann insisted that his Afrezza inhaled insulin device would be a winner. And the Los Angeles billionaire repeatedly bet part of his own fortune on winning FDA approval, despite skepticism that such a device may not gain acceptance and, more specifically, changes in strategy and hyperbolic statements that set some Wall Streeters on edge (look here). Now, less than three weeks after the FDA issued yet another complete response letter (see here), Mann appears to have finally given up. Actually, he used slightly different language. To wit, MannKind reported a loss for the year; disclosed plans to lay off 179 employees or 41 percent of its workforce, and now has less than a year’s worth of cash left (see statement). In the past, cash was not a problem. Mann woul... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4464704 Fri, 11 Feb 2011 13:48:09 +0100 4464704 http://www.medworm.com/index.php?rid=4139478&cid=t_118065_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F8b4V5ZDEQ4A%2F John Arditi has created quite a stir. The former senior director for worldwide regulatory affairs at MannKind recently filed a wrongful termination lawsuit against the drugmaker for allegedly retaliating against him after he insisted on reporting to the FDA what he believed was misconduct at clinical trial sites in Russia and Bulgaria (back story). After the news broke, MannKind released a statement saying an independent investigator was hired to review the data, which is being gathered to support approval for the Afrezza inhaled insulin device, and that “there was no evidence of any deception or intent on the part of MannKind to deceive the FDA.” That leaves open the question as to whether Arditi spotted real fraud, although cfo Matt Pfeffer is quoted as saying the claims have... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4139478 Fri, 05 Nov 2010 15:32:21 +0100 4139478 http://www.medworm.com/index.php?rid=3652689&cid=t_118065_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fxb0a6xv_dLM%2F The long-running and expensive quest by Alfred Mann, a Los Angeles billionaire and philanthropist, to develop an inhaled insulin device took another odd turn this week. His company, which has the not-so-modest name of MannKind, has already irritated investors by what some Wall Streeters say has been a lot of hype over opportunities for potential marketing partners and, importantly, FDA approval. Disappointment and skepticism mounted, in fact, last March, when the FDA issued a complete response letter. Given that Mannkind must resubmit a new drug application for its Afrezza inhaler, any meeting with the FDA would be significant, especially since the plan now calls for switching devices. Yet, MannKind execs not only downplayed a recent ‘end-of-review’ meeting, but practically hid... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3652689 Fri, 11 Jun 2010 14:07:22 +0100 3652689 http://www.medworm.com/index.php?rid=3370672&cid=t_118065_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fc1K953fiV_U%2F Rise and shine. Another day is under way. And so, momentarily, we will rouse our short people from their slumber. Meanwhile, we have gathered a few items for your perusal as you steel yourselves for the latest round of meetings and deadlines. AstraZeneca Will Be Selective About Branded Generics (Reuters) Canada Will Revamp Pandemic Vaccine Supplies (The Globe & Mail) Genetic Test Can Cut Warfarin Hospitalizations (Reuters) Abbott’s CEO Pay Fell On Reduced Stock Options (Associated Press) FDA Seeks More Data On MannKind’s Inhaled Insulin (Reuters) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3370672 Tue, 16 Mar 2010 12:03:12 +0100 3370672 http://www.medworm.com/index.php?rid=3159976&cid=t_118065_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FKhMI9Q2pf74%2F In a surprising development, the FDA delayed review of Mannkind’s insulin inhaler, because an inspection of a manufacturing plant hasn’t been completed. In a statement, Mannkind ceo Alfred Mann says the company believes all other such sites have been inspected, clinical trials are complete and there are no other outstanding FDA questions unanswered. FDA approval had been expected by Jan. 16 and as recently as a week ago, Mannkind execs indicated the regulatory okay was on its way. Now, though, it’s not clear when approval will be made and a source close to the company tells TheStreet that the “FDA messed up,” because Mannkind execs were supposedly led to believe inspections were completed. Mann, an elderly Los Angeles billionaire and philanthropist, has repor... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3159976 Mon, 11 Jan 2010 13:20:19 +0100 3159976 http://www.medworm.com/index.php?rid=2999749&cid=t_118065_134_f&fid=34841&url=http%3A%2F%2Fwww.diabetesmine.com%2F2009%2F11%2Fthe-truth-about-afresa-inhalable-insulin-a-chat-with-al-mann.html Al Mann, CEO of MannKind Corp., is something of a legend in his own time.  He not only founded MiniMed, acquired by Medtronic, but also four other successful medical companies. He’s a billionaire, with his own Biomedical Engineering Institute at the University of Southern California (USC), so we can assume that he’s not just championing [...] (Source: Diabetes Mine) Diabetes Mine blogs http://www.medworm.com/rss/comments.php?id=2999749 Tue, 17 Nov 2009 16:02:31 +0100 2999749 http://www.medworm.com/index.php?rid=2883170&cid=t_118065_134_f&fid=34841&url=http%3A%2F%2Fwww.diabetesmine.com%2F2009%2F10%2Fmixed-feelings-on-inhalable-insulin.html MannKind Corp., the most aggressive company pushing ahead on bringing inhalable insulin to market post the Exubera debacle, took a hit last week when it was forced to announce that a critical marketing partnership didn’t pan out.  Investors are now fighting over the company’s future. As a PWD who watched the whole sordid Exubera story play [...] (Source: Diabetes Mine) Diabetes Mine blogs http://www.medworm.com/rss/comments.php?id=2883170 Mon, 12 Oct 2009 13:00:29 +0100 2883170 http://www.medworm.com/index.php?rid=2649220&cid=t_118065_134_f&fid=36012&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FBattleDiabetes%2F%7E3%2FzSYv4DnN2sg%2F The pharmaceutical company Pfizer has decided to discontinue their inhaled insulin Exubera. The inhaled insulin Exubera was classified as a second generation form of insulin and it was thought that this development in insulin technology would take off…didn’t happen. But why? Pfizer has reported that Exubera, which was an inhaled powder insulin product geared towards type1 and type2 diabetes, never found the acceptance of doctors and patients. Pfizer announced on October 18th that they will no longer be producing Exubera, their announcement did make it clear that their discontinuation of the Inhaled Insulin Device decision was not based on any safety issues, it was totally due to lack of interest. In other words, they were not making enough money off of Exubera to make it wort... Battle Diabetes Blog blogs http://www.medworm.com/rss/comments.php?id=2649220 Tue, 28 Jul 2009 13:38:49 +0100 2649220 http://www.medworm.com/index.php?rid=2325153&cid=t_118065_134_f&fid=35152&url=http%3A%2F%2Fsstrumello.blogspot.com%2F2009%2F04%2Fwelcome-back.html No, I'm not referring to the cheesy 1970's TV show starring John Travolta. But with the New Year already well underway (by more than 3 months, no less), I know its been quite a while since my last blog posting. Since April 1st was my birthday, I decided to post to let everyone know I haven't disappeared (and as Mark Twain once wrote "Reports of my demise have been greatly exaggerated"). I've been very quiet on the blogging front for the past few months, and I had a good reason (I really don't need a reason but I have one anyway): I was in the process of moving into a new place. I did the move mostly by myself (meaning no movers), and mostly when I had free time (meaning on the weekends and evenings, basically all of my "free" time). Of course, I still have a job to occupy my time during no... Scott's Web Log blogs http://www.medworm.com/rss/comments.php?id=2325153 Fri, 03 Apr 2009 12:00:00 +0100 2325153 http://www.medworm.com/index.php?rid=1365032&cid=t_118065_136_f&fid=36051&url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FCancerCommentary%2F%7E3%2F268056487%2F Inhaled insulin (Pfizer’s Exubera) may be associated with lung cancer. Such were the findings revealed by a clinical trial, in turn prompting Pfizer to update its product labeling. The data demonstrate that six of 4,740 patients treated with the inhaled powder form of recombinant human insulin (Exubera, Pfizer) developed lung cancer, compared with one of 4,292 patients not treated with the therapy. One inhaled insulin-treated patient also reported primary lung malignancy in a post-marketing report. Though unrelated to this new date, Pfizer apparently will stop the marketing of Exubera in October. Hmmm…could really be unrelated? Read more from Endocrine Today. Tags: Exubera, inhaled insulin, lung-cancer, PfizerShare This (Source: Cancer Commentary) Cancer Commentary blogs http://www.medworm.com/rss/comments.php?id=1365032 Fri, 11 Apr 2008 01:22:06 +0100 1365032 http://www.medworm.com/index.php?rid=1294729&cid=t_118065_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F249462697%2F The biotech won’t give up. Despite Lilly’s decision last week to abandon such a product, MannKind pledged to continue developing its insulin inhaler system even though its stock fell in reaction to Lilly’s announcement, The Los Angeles Times reports. But Hakan Edstrom, MannKind’s president, insists the stock, which has lost more than two-thirds of its value in the last year, will bounce back once investors realized its device is superior to the one Lilly had been pursuing. “We’ve been affected by an ongoing flu in the inhaler market, but we’re confident that we’ll come out of this with flying colors,” he tells the Times. “People are looking at all the inhalers as one family without a clear understanding that we have a very differe... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1294729 Tue, 11 Mar 2008 11:58:42 +0100 1294729 http://www.medworm.com/index.php?rid=1286444&cid=t_118065_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F247566513%2F Call it the Exubera factor. Alkermes says Lilly expects to walk away from the diabetes device within the week, the second time in less than a year that a big drugmaker decided an insulin inhaler lacks commercial prospects. Pfizer, you may recall, famously failed to properly market Exubera and, last fall, walked away, but not before suffering tremendous embarassment over its weak promotional efforts. Despite the rejection from Lilly, Alkermes hopes to complete Phase III testing, which is expected to finish this year. “Data from these studies will provide patients, physicians and the scientific community with long-awaited and important data for the evaluation of new diabetes medications,” Alkermes says, somewhat defiantly in a statement. Still, this may be a hard sell. Initially,... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1286444 Fri, 07 Mar 2008 19:58:27 +0100 1286444 http://www.medworm.com/index.php?rid=1286291&cid=t_118065_134_f&fid=35152&url=http%3A%2F%2Fsstrumello.blogspot.com%2F2008%2F03%2Fanother-inhaled-insulin-dies-but-not.html Today, it looks like Eli Lilly and Company's AIR inhaled insulin product has been killed. This follows Pfizer's Exubera disaster, and Novo Nordisk's announcement that they were pulling the plug on its AERx iDMS inhaled insulin product.But what makes this announcement so unusual is that the insulin-maker (in this case, Lilly) wasn't behind the decision, but the partner (in this case, Alkermes). Today, Alkermes put out an unusual, pre-emptive press release saying it expects Lilly to discontinue the program in the next week, ending their 7-year partnership to develop an inhaled insulin. No doubt, Lilly had its own questions considering the moves of its main rivals. In fact, Lilly had told Alkermes that the company was "evaluating its business case" for their AIR insulin product, which was in ... Scott's Web Log blogs http://www.medworm.com/rss/comments.php?id=1286291 Fri, 07 Mar 2008 19:30:00 +0100 1286291 http://www.medworm.com/index.php?rid=1150712&cid=t_118065_134_f&fid=35152&url=http%3A%2F%2Fsstrumello.blogspot.com%2F2008%2F01%2Fnovos-aerx-inhaled-insulin-also-bites.html Wow! Just a few years ago, many on Wall Street were convinced that Pfizer's Exubera was going to be a surefire blockbuster. We all know how that turned out (see here for my chronicling of that business debacle).More recently, the worldwide insulin market leader, Novo Nordisk A/S has tried to temper expectations for their own inhaled insulin product, which the company anticipated bringing to market by 2009 or 2010. In a November 6, 2007 interview with Dow Jones, a Novo executive said the company thought that the AERx iDMS inhaled insulin product it has been developing would be a niche product, not a blockbuster."We don't think for us it's a blockbuster," Martin Soeters, president of Novo Nordisk's U.S. unit, said on November 6, 2007 at a pharmaceutical industry conference in Philadelphia.So... Scott's Web Log blogs http://www.medworm.com/rss/comments.php?id=1150712 Mon, 14 Jan 2008 22:00:00 +0100 1150712 http://www.medworm.com/index.php?rid=1455519&cid=t_118065_134_f&fid=36985&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2Fsugarstats%2F%7E3%2F186234139%2F For those of you out there still wishing for an better inhaled insulin solution there just might be hope yet. Or at least as long as Alfred E. Mann can help it. He believes in it so much he is going to invest $966 Million of his own money. “I believe this is one of [...] (Source: SugarStats.com - Simple, Online Blood Sugar Tracking for Diabetes Management) SugarStats.com - Simple, Online Blood Sugar Tracking for Diabetes Management blogs http://www.medworm.com/rss/comments.php?id=1455519 Sat, 17 Nov 2007 12:00:02 +0100 1455519 http://www.medworm.com/index.php?rid=979535&cid=t_118065_134_f&fid=36012&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FBattleDiabetes%2F%7E3%2F174878547%2F The pharmaceutical company Pfizer has decided to discontinue their inhaled insulin Exubera. The inhaled insulin Exubera was classified as a second generation form of insulin and it was thought that this development in insulin technology would take off…didn’t happen. But why? Continue Reading Inhaled Insulin Exubera by Pfizer Discontinued? What Happened? (Source: Battle Diabetes Blog) Battle Diabetes Blog blogs http://www.medworm.com/rss/comments.php?id=979535 Thu, 25 Oct 2007 12:48:38 +0100 979535 http://www.medworm.com/index.php?rid=949976&cid=t_118065_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F169742746%2F That’s the message from some Wall Street analysts to the drugmaker, which is hoping to succeed where Pfizer failed. For those who don’t recall, Pfizer’s insulin inhaler was a colossal flop, generating meager sales and countless jokes to the point where the bong-like device became a symbol of the company’s systemic troubles. (Don’t believe us? Take a look at how some are using Exubera now). Lilly’s own device, which is about the size of a cell phone, is still two years away from the hitting the market. But Lilly execs are talking up their prospects every chance they get. “Some patients get burned out from four or five injections a day,” Carlos Paya, vp of Lilly Research Laboratories and team leader of the inhaled insulin project, tells The In... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=949976 Sun, 14 Oct 2007 13:24:21 +0100 949976 http://www.medworm.com/index.php?rid=906268&cid=t_118065_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F161516074%2F Take a look, folks. The drugmaker’s inhaled insulin gizmo is about the size of some cell phones or an iPod, which means it can be used so much more discreetly than Pfizer’s bong. Despite a new sales and advertising push, Exubera isn’t expected to survive, not after racking up measly sales. In fact, some people are now using the Pfizer device as a birdfeeder. Are Christmas ornaments next? Of course, safety and effectiveness must still be established, given concerns over the affect on the lungs. A late-stage trial is slated to wrap in time for the firm to submit the product in 2009. Naturally, Bryce Carmine, Lilly’s global brand director told the UBS Global Life Sciences Conference, that he’s “encouraged” by the safety of inhaled insuling, according ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=906268 Wed, 26 Sep 2007 13:04:46 +0100 906268 http://www.medworm.com/index.php?rid=716535&cid=t_118065_87_f&fid=34867&url=http%3A%2F%2Fwww.thediabetesblog.com%2F2007%2F07%2F05%2Freview-of-inhaled-insulin-research-reveals-a-mixed-bag-for-type%2F Filed under: Type 2, Adult Onset, Drugs, ResearchInhaled insulin was approved by the Food and Drug Administration in 2006. A new review of the body of published research on inhaled insulin reveals positive and negative results. Keep in mind, this body of research is lean and only covers a six month window of follow-up. Researchers examined eight studies involving 1,881 patients with type 2 diabetes to compare inhaled insulin, injected insulin and oral medications. On the positive side, inhaled insulin worked as well as short-acting injected insulin to control blood sugar over three months. Inhaled insulin can also improve blood glucose control for type 2s who have not had good results with short-acting insulin taken on top of baseline insulin. But inhaled insulin users had more difficult... The Diabetes Blog blogs http://www.medworm.com/rss/comments.php?id=716535 Thu, 05 Jul 2007 04:00:00 +0100 716535